Issue Date: April 16, 2012
GS-9620 by Gilead Sciences and BMS-791325 by Bristol-Myers Squibb
Randall L. Halcomb, director of medicinal chemistry at Gilead Sciences in Foster City, Calif., revealed the structure of GS-9620, a potential drug for chronic hepatitis B as well as hepatitis C. The molecule is an orally administered agonist of Toll-like receptor 7 (TLR7), a receptor on immune cells that responds to virusderived RNA. Gilead’s scientists had a specific reason for targeting the immune system, Halcomb told C&EN. “In general when a hepatitis B patient goes . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society